EUVIMEDEUVIMED entdecken
Crossref

Risperidone Long-Acting Injection (Okedi)

CDA-AMC

Canadian Journal of Health Technologies · 13.05.2026 · 6 (5)

DOI: 10.51731/cjht.2026.1439 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 13.05.2026. Verfasst von CDA-AMC.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses risperidone long-acting injection (Okedi), 75 mg or 100 mg, powder for extended-release suspension, intramuscular injection. Indication: The treatment of schizophrenia in adults.

Zitieren

APA

CDA-AMC (2026). Risperidone Long-Acting Injection (Okedi). Canadian Journal of Health Technologies, 6(5). https://doi.org/10.51731/cjht.2026.1439

Vancouver

CDA-AMC. Risperidone Long-Acting Injection (Okedi). Canadian Journal of Health Technologies. 2026;6(5). doi:10.51731/cjht.2026.1439

BibTeX
@article{CDAAMC2026,
  author = {CDA-AMC},
  title = {Risperidone Long-Acting Injection (Okedi)},
  journal = {Canadian Journal of Health Technologies},
  year = {2026},
  volume = {6},
  number = {5},
  doi = {10.51731/cjht.2026.1439}
}
Kostenlos starten →